Physics-informed deep learning sharpens nano diagnostics for elusive pancreatic cancer

Area of Science:

• Oncology
• Medical Imaging
• Artificial Intelligence

Background:

• Pancreatic cancer (PC) affects over 10% of the global population, characterized by late onset and poor prognosis.
• Current screening methods, including imaging and biomarkers, lack sensitivity for high-risk individuals.
• Existing treatments like chemotherapy and surgery have limited eligibility and high recurrence rates.

Purpose of the Study:

• To explore the potential of emerging technologies in improving pancreatic cancer diagnostics and treatment.
• To highlight the role of AI, nanomedicine, and advanced imaging in early detection and personalized care.
• To discuss the integration of physics-informed models for enhanced prediction accuracy in oncology.

Main Methods:

• Review of emerging technologies such as physics-informed deep learning (PIDL), artificial intelligence (AI), and nanomedicine.
• Analysis of AI-driven radiomics for individualized diagnosis and drug delivery.
• Exploration of hybrid model methodologies and computational drug development.
• Evaluation of liquid biopsy technologies for early diagnosis and personalized treatment.

Main Results:

• AI and PIDL enhance early detection by efficiently evaluating images and synthesizing data.
• Nanomedicine and AI-driven radiomics enable personalized diagnoses, improved drug delivery, and management of the tumor microenvironment.
• Hybrid models and computational drug development increase prediction precision in oncology research.
• Liquid biopsy and integrated AI approaches show promise for early diagnosis and tailored treatment strategies.

Conclusions:

• The integration of AI, advanced imaging, nanomedicine, and physics-informed models holds significant potential to revolutionize pancreatic cancer diagnostics.
• These emerging technologies can substantially enhance early detection rates and improve patient prognoses for pancreatic cancer.
• A multidisciplinary approach combining these advanced tools is crucial for transforming pancreatic cancer care.